Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Efficacy and Safety of Two Hair Supplements in Men With Androgenic Alopecia

1. september 2026 opdateret af: Activ'inside

Clinical Efficacy and Safety of Two Food Supplements on Hair Health in Caucasian Male Subjects With Androgenic Alopecia : a Multicentric, Randomised, Double-blind, Placebo-controlled Clinical Study

The goal of this clinical trial is to evaluate the efficacy and safety of two different formulations of a food supplement on hair health in healthy Caucasian male subjects aged 35 to 65 years with mild to moderate androgenetic alopecia. The main questions it aims to answer are:

  • Whether the two formulations improve hair growth and reduce hair loss after 42 and 84 days, as assessed by phototricogram parameters.
  • Whether the two formulations improve hair brightness, and colour lightness after 42 and 84 days, as assessed by spectrophotometer/colorimeter.

Researchers will compare two active supplement groups and a placebo group to determine whether the active products improve objective hair parameters and perceived hair quality.

Participants will:

  • be randomized to one of three groups : Active 1, Active 2 or Placebo;
  • take one capsule daily at breakfast for 84 days;
  • attend clinical visits at baseline, Day 42, and Day 84;
  • undergo hair assessments including pull test, phototrichogram, and spectrophotometer/colorimeter measurements;
  • complete a self-assessment questionnaire at follow-up visits;
  • be monitored for safety and tolerability throughout the study.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

99

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

  • Italien
    • Cosenza
      • Rende, Cosenza, Italien
        • Nutratech S.r.l. - Via Francesco Todaro 20/22
    • Ferrare
      • Ferrara, Ferrare, Italien
        • Complife Italia S.r.l. - Via Mortara 171
    • Milan
      • Garbagnate Milanese, Milan, Italien
        • Complife Italia S.r.l. - Via Signorelli 159
      • Milan, Milan, Italien
        • Complife Italia S.r.l. - Piazzale Siena 11
    • Pavia
      • Biella, Pavia, Italien
        • Complife Italia SRL - Corso San Maurizio 25
      • San Martino Siccomario, Pavia, Italien

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  1. Healthy male subjects
  2. Subjects of Caucasian ethnicity
  3. Subjects aged between 35 and 65 years (extremes included)
  4. Subjects with mild to moderate androgenetic alopecia, corresponding to the grade II to III vertex on Hamilton-Norwood scale
  5. Subjects with hair that is at least 5-7 cm long
  6. Subjects with visible grey or white hair
  7. Subjects registered with national health service
  8. Subjects certifying the truthfulness of the personal data disclosed to the Principal Investigator or designated personnel
  9. Subjects able to understand the language used in the investigation center and the information given by the Principal Investigator or designated personnel
  10. Subjects able to respect the instructions given by the Principal Investigator or designated personnel as well as able to respect the study constraints and specific requirements
  11. Subjects who commit not to change their daily routine or lifestyle during the study*
  12. Subjects on stable pharmacological therapy (except for the pharmacological therapy in the non-inclusion criteria) for at least one month without any changes expected or planned during the study

  13. Subjects informed about the test procedures who have signed a consent form and privacy agreement

    • Subjects are asked not to change their usual hair hygiene and styling products (such as shampoo, conditioner, hair gel, hairspray, etc.) throughout the study

Exclusion Criteria:

  1. Subjects who do not meet the inclusion criteria
  2. Subjects with any acute, chronic, or progressive disease or condition that may interfere with the study data or that the Principal Investigator considers dangerous to the subject or incompatible with the requirements of the study **
  3. Subjects participating or planning to participate in other clinical trials
  4. Subjects who participated in a similar study without respecting an adequate washout period (at least one month)
  5. Subjects that have food intolerances or food allergies to ingredients of the study product
  6. Subjects under pharmacological treatments that are considered incompatible with the study requirement by the Principal Investigator ***
  7. Subjects who are currently using food supplement(s) and/or products with the same activity as the study product, or who haven't observed an adequate washout period (at least one month)
  8. Subjects admitted to a health or social facility
  9. Subjects planning a hospitalization during the study
  10. Subjects not able to be contacted in case of emergency
  11. Subjects deprived of freedom by administrative or legal decision or under guardianship
  12. Subjects who have or have had a history of alcohol or drug addiction

  13. Subjects with eating disorders (i.e. bulimia, psychogenic eating disorders, etc.)

    • Including oncological diseases, diabetes, autoimmune diseases, acute inflammatory diseases, ongoing infectious diseases, and alopecia areata.

      • Including corticosteroid drugs, biological drugs, and cytostatic drugs.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Active product 1
hard shell capsule containing green tea leaf extract (Camellia sinensis (L.) Kuntze, Theaceae), bamboo shoot extract (Bambusa vulgaris Schrad., Poaceae), and selenium-enriched yeast (Saccharomyces cerevisiae) and maltodextrin
Kosttilskud: formulation of green tea leaf extract, bamboo shoot extract and selenium-enriched yeast
one capsule per day during breakfast with water for 84 days
Aktiv komparator: Active product 2
hard shell capsule containing grape seed extract (Vitis vinifera L., Vitaceae), bamboo shoot extract (Bambusa vulgaris Schrad., Poaceae), and selenium-enriched yeast (Saccharomyces cerevisiae) and maltodextrin
Kosttilskud: formulation of grape seed extract, bamboo shoot extract and selenium-enriched yeast
one capsule per day during breakfast with water for 84 days
Placebo komparator: Placebo
hard shell capsule containing maltodextrin
Kosttilskud: Placebo (maltodextrin)
one capsule per day during breakfast with water for 84 days

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in anagen hair density
Tidsramme: 42 and 84 days
Number of hairs in anagen phase per cm² and proportion (in %) using phototricogram (TrichoScan)
42 and 84 days

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Total number of hair in anagen phase
Tidsramme: 42 and 84 days
= (Anagen hair after supplement use x scalp surface) - (Anagen hair before supplement use x scalp surface) where the scalp surface is 580 cm2.
42 and 84 days
Change in telogene hair density
Tidsramme: 42 and 84 days
Number of hairs in telogen phase per cm² and proportion (in %) using phototricogram (TrichoScan)
42 and 84 days
Number of hair protected against falling out (HPF)
Tidsramme: 42 ans 84 days

(TEAF x SH) - (TEBE x SH)

where: TEAF is the number of telogen hair after supplement use ; TEBE is the number of telogen hair before product use; SH is the head surface (580cm2).
42 ans 84 days
Change in total hair density
Tidsramme: 42 and 84 days
Number of total hairs per cm² using phototricogram (TrichoScan)
42 and 84 days
Change in hair brightness
Tidsramme: 42 and 84 days
Hair brightness is measured on 5 points near the hairline using a spectrophotometer/colorimeter CM 700D (Konica-Minolta). The measured parameter is the 8° gloss value (average value of the 5 measures).
42 and 84 days
Change in hair colour lightness
Tidsramme: 42 and 84 days
Hair color lightness is measured on 5 points near the hairline using a spectrophotometer/colorimeter CM 700D (Konica-Minolta). The measured parameter is the L* parameter (average value of the 5 measures) indicating the hair color lightness (i.e. lighter or darker hair).
42 and 84 days

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Self-assessment questionnaire
Tidsramme: 42 and 84 days
Subjects are asked to reply to a self-assessment questionnaire to assess the efficacy perceived and the pleasantness of the product. Responses are provided spontaneously, without external influence.
42 and 84 days

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Activ'inside

Efterforskere

  • Ledende efterforsker: Enza Cestone, Dr, Complife Italia Srl

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

30. september 2026

Primær færdiggørelse (Anslået)

1. februar 2027

Studieafslutning (Anslået)

1. februar 2027

Datoer for studieregistrering

Først indsendt

27. august 2026

Først indsendt, der opfyldte QC-kriterier

1. september 2026

Først opslået (Faktiske)

8. september 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

8. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • EC_0000367/2026

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

confidential data

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner